Two Sigma Investments LP Sells 53,247 Shares of Fresenius Medical Care AG (NYSE:FMS)

Two Sigma Investments LP trimmed its stake in Fresenius Medical Care AG (NYSE:FMS - Free Report) by 38.4% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 85,399 shares of the company's stock after selling 53,247 shares during the quarter. Two Sigma Investments LP's holdings in Fresenius Medical Care were worth $1,933,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Millennium Management LLC boosted its position in shares of Fresenius Medical Care by 5,297.5% in the fourth quarter. Millennium Management LLC now owns 722,238 shares of the company's stock worth $16,351,000 after buying an additional 708,857 shares during the period. ABC Arbitrage SA acquired a new stake in shares of Fresenius Medical Care in the fourth quarter worth $4,215,000. OLD Mission Capital LLC acquired a new stake in shares of Fresenius Medical Care in the fourth quarter worth $3,545,000. Broyhill Asset Management acquired a new stake in shares of Fresenius Medical Care in the fourth quarter worth $3,412,000. Finally, Integral Health Asset Management LLC boosted its position in shares of Fresenius Medical Care by 33.3% in the fourth quarter. Integral Health Asset Management LLC now owns 600,000 shares of the company's stock worth $13,584,000 after buying an additional 150,000 shares during the period. 8.37% of the stock is currently owned by institutional investors and hedge funds.

Fresenius Medical Care Stock Up 1.6%

Shares of FMS stock traded up $0.44 on Thursday, hitting $28.65. The company's stock had a trading volume of 344,413 shares, compared to its average volume of 332,881. The stock has a market capitalization of $16.81 billion, a price-to-earnings ratio of 23.68, a P/E/G ratio of 0.76 and a beta of 0.85. Fresenius Medical Care AG has a fifty-two week low of $17.93 and a fifty-two week high of $30.46. The firm's fifty day moving average price is $26.20 and its 200-day moving average price is $24.41. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.37 and a quick ratio of 1.02.

Fresenius Medical Care (NYSE:FMS - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported $0.44 earnings per share for the quarter, topping analysts' consensus estimates of $0.43 by $0.01. The company had revenue of $5.54 billion during the quarter, compared to analysts' expectations of $4.71 billion. Fresenius Medical Care had a return on equity of 6.04% and a net margin of 3.43%. Research analysts anticipate that Fresenius Medical Care AG will post 1.51 EPS for the current year.

Fresenius Medical Care Increases Dividend

The business also recently announced an annual dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 23rd will be given a dividend of $0.7871 per share. The ex-dividend date of this dividend is Friday, May 23rd. This represents a yield of 1.9%. This is a boost from Fresenius Medical Care's previous annual dividend of $0.44. Fresenius Medical Care's dividend payout ratio is presently 49.11%.

Analyst Ratings Changes

Several analysts have recently commented on FMS shares. Truist Financial raised their target price on Fresenius Medical Care from $25.00 to $30.00 and gave the stock a "hold" rating in a research report on Monday, May 12th. Wall Street Zen assumed coverage on Fresenius Medical Care in a research note on Tuesday, May 20th. They set a "strong-buy" rating for the company. Finally, Morgan Stanley reiterated an "underweight" rating on shares of Fresenius Medical Care in a report on Thursday, May 15th. One analyst has rated the stock with a sell rating, two have issued a hold rating, one has issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $27.80.

Fresenius Medical Care Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.